Trial intelligence / Profile preview

Lamazym Aftercare in Alpha-Mannosidosis

NCT01908725Phase 3Completed

Sponsor
Chiesi Farmaceutici S.p.A.
Start
Jun 2013
Primary completion
Sep 2022
Modality
Replacement Enzymes
Countries
1
01

Overview

A Phase 3 trial of velmanase alfa in alpha-mannosidosis, sponsored by Chiesi Farmaceutici S.p.A.. Started Jun 2013; status: completed.

02

Drugs

velmanase alfa
03

Conditions

alpha-mannosidosis

Beyond the preview

Go deeper on NCT01908725.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01908725.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call